International Clinical Trial: A single-center, single-arm clinical study on the efficacy and safety of Iparomlimab and Tuvonralimab combined with chemotherapy as neoadjuvant therapy in patients with muscle-Invasive bladder cancer (MIBC)

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115561) titled 'A single-center, single-arm clinical study on the efficacy and safety of Iparomlimab and Tuvonralimab combined with chemotherapy as neoadjuvant therapy in patients with muscle-Invasive bladder cancer (MIBC)' on Dec. 29, 2025.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Tianjin Cancer Hospital Airport Hospita

Condition: Muscle invasive bladder cancer

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-01-01

Target Sample Size: Experimental group:20;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj...